{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:19:40Z","timestamp":1790651980152,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jneuroim.2025.578591","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T04:28:19Z","timestamp":1742617699000},"page":"578591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparison of clinical features of aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein associated disorder (MOGAD), and double seronegative NMOSD - A single center experience"],"prefix":"10.1016","volume":"403","author":[{"given":"Melike","family":"Cakan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi","family":"Demirel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bar\u0131\u015fcan","family":"Cimen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazire P\u0131nar Acar","family":"\u00d6zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lksen","family":"\u00c7olpak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Karabudak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asl\u0131","family":"Tuncer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jneuroim.2025.578591_bb0005","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.neurol.2018.02.084","article-title":"Neuromyelitis optica spectrum disorders: features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes","volume":"174","author":"Alves Do Rego","year":"2018","journal-title":"Rev. Neurol. (Paris)"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578591_bb0010","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/ijo.IJO_887_21","article-title":"Clinical profile, imaging features and short term visual outcomes of Indian optic neuritis patients with and without seromarkers for myelin oligodendrocyte glycoprotein and neuromyelitis optica","volume":"70","author":"Ambika","year":"2022","journal-title":"Indian J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578591_bb0015","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578591_bb0020","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200188","article-title":"Serum biomarker profiles discriminate AQP4 seropositive and double seronegative neuromyelitis optica spectrum disorder","volume":"11","author":"Carta","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2025.578591_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102399","article-title":"Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica","volume":"45","author":"Ciotti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578591_bb0030","first-page":"1131","article-title":"Neuromyelitis optica spectrum disorders","volume":"28","author":"Costello","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578591_bb0035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s13760-021-01712-3","article-title":"Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort","volume":"122","author":"Dauby","year":"2022","journal-title":"Acta Neurol. Belg."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578591_bb0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.25259\/JNRP_8_2022","article-title":"Comparison of clinico-radiological profile, optical coherence tomography parameters, and outcome in MOGAD and Neuromyelitis optica spectrum disorder subtypes: a prospective observational study","volume":"14","author":"Dhar","year":"2023","journal-title":"J. Neurosci. Rural Pract."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578591_bb0045","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578591_bb0050","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/mds.26694","article-title":"Minimal clinically important worsening on the progressive supranuclear palsy rating scale","volume":"31","author":"Hewer","year":"2016","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578591_bb0055","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin. Med."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578591_bb0060","doi-asserted-by":"crossref","first-page":"327","DOI":"10.25259\/JNRP_59_2022","article-title":"Therapeutic response to rituximab in seropositive neuromyelitis optica: experience from a tertiary care center in South India","volume":"14","author":"James","year":"2023","journal-title":"J. Neurosci. Rural Pract."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578591_bb0065","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578591_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102921","article-title":"Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges","volume":"21","author":"Liu","year":"2022","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578591_bb0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of Neuromyelitis Optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578591_bb0080","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.autrev.2010.09.021","article-title":"Devic\u2019s syndrome and SLE: challenges in diagnosis and therapeutic possibilities based on two overlapping cases","volume":"10","author":"Polg\u00e1r","year":"2011","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578591_bb0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10072-022-06409-w","article-title":"Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina","volume":"44","author":"Rojas","year":"2023","journal-title":"Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578591_bb0090","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jim-2019-001126","article-title":"CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease","volume":"68","author":"Rosenthal","year":"2020","journal-title":"J. Investig. Med."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578591_bb0095","doi-asserted-by":"crossref","first-page":"313","DOI":"10.25259\/JNRP_32_2022","article-title":"A comparative analysis of demographic, clinical and imaging features of myelin oligodendrocyte glycoprotein antibody positive, aquaporin 4 antibody positive, and double seronegative demyelinating disorders - an Indian tertiary care center prospective study","volume":"14","author":"Salunkhe","year":"2023","journal-title":"J. Neurosci. Rural Pract."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578591_bb0100","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578591_bb0105","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10072-023-07050-x","article-title":"Clinical and demographic characteristics of patients with NMOSD: a longitudinal retrospective analysis of a Slovak cohort of 63 patients","volume":"45","author":"Szilasiov\u00e1","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2025.578591_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103907","article-title":"A quarter-century report on neuromyelitis optica spectrum disorder in Thailand: a single-center tertiary care cohort","volume":"63","author":"Tisavipat","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578591_bb0115","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578591_bb0120","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578591_bb0125","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"11\u221212","key":"10.1016\/j.jneuroim.2025.578591_bb0130","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Wu","year":"2023","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578591_bb0135","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00415-019-09685-3","article-title":"Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population","volume":"267","author":"Zhang","year":"2020","journal-title":"J. Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825000712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825000712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T03:51:40Z","timestamp":1746071500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572825000712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"alternative-id":["S0165572825000712"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578591","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of clinical features of aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein associated disorder (MOGAD), and double seronegative NMOSD - A single center experience","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578591"}}